See more : SIM Technology Group Limited (912000.TW) Income Statement Analysis – Financial Results
Complete financial analysis of eFFECTOR Therapeutics, Inc. (EFTR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of eFFECTOR Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Innovative Eyewear, Inc. (LUCY) Income Statement Analysis – Financial Results
- Western Capital Resources, Inc. (WCRS) Income Statement Analysis – Financial Results
- Cineline India Limited (CINELINE.BO) Income Statement Analysis – Financial Results
- Hualan Biological Bacterin Inc. (301207.SZ) Income Statement Analysis – Financial Results
- Civista Bancshares, Inc. (CIVB) Income Statement Analysis – Financial Results
eFFECTOR Therapeutics, Inc. (EFTR)
About eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 3.55M | 1.43M | 42.00M | 0.00 |
| Cost of Revenue | 22.92M | 53.00K | 24.00K | 21.83M | 307.00K |
| Gross Profit | -22.92M | 3.50M | 1.41M | 20.17M | -307.00K |
| Gross Profit Ratio | 0.00% | 98.51% | 98.32% | 48.02% | 0.00% |
| Research & Development | 22.92M | 23.31M | 19.96M | 21.83M | 23.58M |
| General & Administrative | 10.93M | 12.64M | 13.37M | 4.35M | 4.72M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.93M | 12.64M | 13.37M | 4.35M | 4.72M |
| Other Expenses | 0.00 | -3.55M | -1.43M | 9.00K | 0.00 |
| Operating Expenses | 33.84M | 32.40M | 31.90M | 26.18M | 28.30M |
| Cost & Expenses | 33.84M | 32.40M | 31.90M | 26.18M | 28.61M |
| Interest Income | 1.95M | 439.00K | 6.00K | 67.00K | 239.00K |
| Interest Expense | 0.00 | 2.25M | 1.76M | 1.33M | 1.38M |
| Depreciation & Amortization | 111.00K | 53.00K | 24.00K | 160.00K | 307.00K |
| EBITDA | -33.73M | -32.40M | -31.90M | 16.06M | -28.30M |
| EBITDA Ratio | 0.00% | -911.99% | -2,230.56% | 38.23% | 0.00% |
| Operating Income | -33.84M | -32.40M | -31.90M | 15.82M | -28.61M |
| Operating Income Ratio | 0.00% | -911.99% | -2,230.56% | 37.66% | 0.00% |
| Total Other Income/Expenses | -1.97M | 9.74M | 47.70M | -1.26M | -1.13M |
| Income Before Tax | -35.81M | -22.67M | 15.80M | 14.56M | -29.74M |
| Income Before Tax Ratio | 0.00% | -637.91% | 1,104.76% | 34.67% | 0.00% |
| Income Tax Expense | 0.00 | -9.74M | -24.00K | 351.00K | 135.14K |
| Net Income | -35.81M | -12.93M | 15.80M | 14.21M | -29.74M |
| Net Income Ratio | 0.00% | -363.83% | 1,104.76% | 33.84% | 0.00% |
| EPS | -16.37 | -7.85 | 9.78 | 23.74 | -53.83 |
| EPS Diluted | -16.37 | -7.85 | 9.78 | 23.74 | -53.83 |
| Weighted Avg Shares Out | 2.19M | 1.65M | 1.62M | 598.56K | 552.43K |
| Weighted Avg Shares Out (Dil) | 2.19M | 1.65M | 1.62M | 598.56K | 552.43K |
Baylor College of Medicine to Present eFFECTOR Therapeutics-Supported Research at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Hold Off on eFFECTOR Therapeutics if You Can't Stomach the Risk
eFFECTOR Therapeutics Stock Might Be Worth the Risk in Small Quantities
eFFECTOR Therapeutics to Participate in 2021 Cantor Virtual Healthcare Conference
What's Going On With eFFECTOR Therapeutics Stock Today?
eFFECTOR: Developing New Class Of Cancer Therapies
Why eFFECTOR Therapeutics Stock Is Heating Up Today
4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351%
EFTR Stock: 7 Things to Know About eFFECTOR as Shares Shoot Up 100%
EFTR Stock: What Is Going on With Red-Hot eFFECTOR Therapeutics Today?
Source: https://incomestatements.info
Category: Stock Reports